{"meta":{"query_hash":"16edabda8aab","filters":{"venue":"Sarcoma Research - International"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/16edabda8aab","api":"https://metacan.xera.ac/api/v1/cohort?venue=Sarcoma+Research+-+International"},"results":[{"id":"W3194091392","doi":"10.26420/sarcomaresint.2021.1047","title":"Real-World Outcomes of Advanced Soft Tissue Sarcoma Patients Treated with Pazopanib","year":2021,"lang":"en","type":"article","venue":"Sarcoma Research - International","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Alberta Cancer Foundation","funders":"","keywords":"Pazopanib; Medicine; Soft tissue sarcoma; Sarcoma; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Chemotherapy; Surgery; Soft tissue; Cancer; Sunitinib; Pathology","score_opus":0.04535030066170792,"score_gpt":0.38899554582832324,"score_spread":0.3436452451666153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194091392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808455,0.0002512438,0.00006125408,0.00007335588,0.0000042340516,0.000014114784,0.0008934607,0.0000031184559,0.0006146848],"genre_scores_gemma":[0.99882394,0.000101262835,0.00004403431,0.000016803855,0.0000073439455,0.000008358743,0.00094123423,0.0000011196584,0.000055891353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99946254,0.00014531569,0.00006939301,0.00009732495,0.0001254458,0.000100029385],"domain_scores_gemma":[0.99708277,0.00025734858,0.0018500591,0.00006619338,0.00029648593,0.0004471871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006819148,0.00015215819,0.00023113635,0.000614858,0.00035480096,0.00084464275,0.0002838022,0.00022922439,0.0012110001],"category_scores_gemma":[0.0023190482,0.00009592242,0.00025758464,0.0010203935,0.00035555148,0.00046220774,0.00046518754,0.00045935932,0.00019843683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019090934,0.000028670735,0.9975999,0.000012253934,0.000038814185,0.00010093003,0.00005863361,0.00012291076,0.000068824695,0.000016881939,0.0001756292,0.0015856469],"study_design_scores_gemma":[0.000018503153,0.00021123336,0.99791974,0.000008865507,0.000033595978,0.00056544645,0.00024899535,0.000358259,0.00008501546,0.00003667295,0.0005066573,0.0000069982143],"about_ca_topic_score_codex":0.0053546266,"about_ca_topic_score_gemma":0.008197906,"teacher_disagreement_score":0.0053546266,"about_ca_system_score_codex":0.0010991269,"about_ca_system_score_gemma":0.0007128049,"threshold_uncertainty_score":0.01064688},"labels":[],"label_agreement":null}]}